240 related articles for article (PubMed ID: 32936306)
1. Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
Zhu X; Ma R; Ma X; Yang G
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32936306
[TBL] [Abstract][Full Text] [Related]
2. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
Riera P; Salazar J; Virgili AC; Tobeña M; Sebio A; Gallano P; Barnadas A; Páez D
Br J Clin Pharmacol; 2018 Jun; 84(6):1389-1392. PubMed ID: 29504153
[TBL] [Abstract][Full Text] [Related]
3. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
[TBL] [Abstract][Full Text] [Related]
4. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
Liu X; Cheng D; Kuang Q; Liu G; Xu W
Pharmacogenomics J; 2014 Apr; 14(2):120-9. PubMed ID: 23529007
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
7. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.
Atasilp C; Biswas M; Jinda P; Nuntharadthanaphong N; Rachanakul J; Hongkaew Y; Vanwong N; Saokaew S; Sukasem C
Clin Transl Sci; 2022 Jul; 15(7):1613-1633. PubMed ID: 35506159
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Campbell JM; Stephenson MD; Bateman E; Peters MD; Keefe DM; Bowen JM
Pharmacogenomics J; 2017 Jan; 17(1):21-28. PubMed ID: 27503581
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Peng H; Duan Z; Pan D; Wen J; Wei X
Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
[TBL] [Abstract][Full Text] [Related]
10. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
12. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
Riera P; Páez D
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1157-1163. PubMed ID: 34486919
[TBL] [Abstract][Full Text] [Related]
14. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Yang Y; Zhou M; Hu M; Cui Y; Zhong Q; Liang L; Huang F
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e479-e489. PubMed ID: 29932297
[TBL] [Abstract][Full Text] [Related]
15. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
16. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
[TBL] [Abstract][Full Text] [Related]
17. Individual Irinotecan Therapy Under the Guidance of Pre-Treated
Lv H; Nie C; He Y; Chen B; Liu Y; Zhang J; Chen X
Technol Cancer Res Treat; 2024; 23():15330338241236658. PubMed ID: 38497131
[No Abstract] [Full Text] [Related]
18. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
[TBL] [Abstract][Full Text] [Related]
19. Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.
Liu X; Cheng D; Kuang Q; Liu G; Xu W
PLoS One; 2013; 8(3):e58489. PubMed ID: 23516488
[TBL] [Abstract][Full Text] [Related]
20. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Han FF; Guo CL; Yu D; Zhu J; Gong LL; Li GR; Lv YL; Liu H; An GY; Liu LH
Cancer Chemother Pharmacol; 2014 Apr; 73(4):779-88. PubMed ID: 24519753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]